论文部分内容阅读
目的探讨实体肿瘤贫血病人血清新喋呤、hepcidin的前体肽(prohepcidin)与促红细胞生成素(EPO)、铁蛋白、C反应蛋白(CRP)等指标的相关性。方法将2009年1月至2010年12月收治的实体肿瘤贫血病人按入组条件纳入治疗组30例,予EPO治疗皮下注射6000IU,每周3次,疗程1个月;同时设良性贫血对照组30例;健康对照组30例。治疗组治疗前后及良性贫血对照组贫血纠正前后,检测新喋呤、prohepcidin、EPO、铁蛋白、CRP、Hb;健康对照组检测新喋呤、prohepcidin、EPO。结果治疗组治疗前新喋呤水平明显高于良性贫血对照组及健康对照组(P=0.000);治疗后明显高于良性贫血对照组(P=0.007)。治疗组治疗前prohepcidin稍低于良性贫血对照组及健康对照组,但差异无统计学意义(P=0.335);治疗后无明显变化,稍低于良性贫血对照组(P=0.409)。治疗前后比较,治疗组、良性贫血对照组的新喋呤、prohepcidin水平差异无统计学意义(P均>0.05)。相关性分析显示,仅良性贫血对照组治疗后新喋呤与VitB12水平有明显相关性(r=0.883,P=0.001);余治疗组、良性贫血对照组治疗前后的prohepcidin与CRP、铁蛋白、EPO水平之间及治疗组治疗前后的新喋呤与VitB12、铁蛋白水平之间,均无相关性(P均>0.05)。结论 prohepcidin不能作为hepcidin检测的替代物;良性贫血与实体肿瘤性贫血患者之间新喋呤水平差异有统计学意义,可用于辅助鉴别贫血病因。
Objective To investigate the correlation between serum neopterin, hepatic prohepcidin and erythropoietin (EPO), ferritin and C-reactive protein (CRP) in solid anemia patients. Methods Thirty patients with anemia of solid tumors who were admitted from January 2009 to December 2010 were enrolled in the treatment group according to the criteria of inclusion group. Subcutaneous injection of 6000IU for EPO was given 3 times a week for 1 month. At the same time, 30 cases; healthy control group of 30 cases. The levels of neopterin, prohepcidin, EPO, ferritin, CRP and Hb in the treatment group before and after treatment and in the anemia control group were detected. Neonates, prohepcidin and EPO were detected in the healthy control group. Results The level of neopterin in treatment group before treatment was significantly higher than that in benign anemia control group and healthy control group (P = 0.000), and was significantly higher than that in benign anemia group after treatment (P = 0.007). The prohepcidin in treatment group was slightly lower than that in benign anemia control group and healthy control group, but the difference was not statistically significant (P = 0.335). There was no significant change after treatment in treatment group, slightly lower than that in benign anemia control group (P = 0.409). Before and after treatment, neopterin and prohepcidin levels in the treatment group and benign anemia control group showed no significant difference (all P> 0.05). Correlation analysis showed that there was a significant correlation between neopterin and VitB12 levels in the control group (r = 0.883, P = 0.001). The levels of prohepcidin, CRP, There was no correlation between EPO levels and neopterin and VitB12 and ferritin levels before and after treatment in the treatment group (all P> 0.05). Conclusion Prohepcidin can not be used as a substitute for hepcidin detection. The difference of neopterin level between benign anemia and solid anemia patients is statistically significant and can be used to identify the cause of anemia.